IDIOPATHIC INFLAMMATORY MYOPATHY
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHY explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHY trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could CAR t cells tame autoimmune diseases? new trial begins
Disease control Recruiting nowThis early-phase study tests a new treatment called CC-97540, which uses a person's own immune cells (CAR T cells) to target and calm the overactive immune system in severe autoimmune diseases like lupus, myositis, scleroderma, and rheumatoid arthritis. The goal is to see if it i…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
CAR T-Cell therapy takes on rare muscle disease
Disease control Recruiting nowThis study tests a new treatment called CABA-201 for people with active idiopathic inflammatory myopathy, a group of rare diseases that cause muscle inflammation and weakness. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells. The goal…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Engineered immune cells take on lupus, scleroderma, and myositis
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. ALLO-329 uses specially engineered immune cells from a donor to target and calm overactive immune cells that cause these diseases. The main goal is to check safety and fi…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHY
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:04 UTC